Sign Out
Dose limiting factor (DLF) of this drug is neutropenia. With the use of this drug, serious bone-marrow suppression (especially neutropenia), serious adverse reactions such as severe infections, and death cases whose causality with this drug cannot be ruled out have been observed. Therefore, cancer chemotherapy including this drug should be performed at medical facilities that can deal with emergency situation under physicians with sufficient knowledge and experience of cancer chemotherapy in only patients who were judged to be proper for the administration of this drug. In addition, patients who are indicated to this drug should be selected carefully, such as not administering this drug to the following patients: Patients with serious bone-marrow suppression; Patients with concomitant infection; Patients with fever suspected infection.
At starting treatment, give adequate explanation about efficacy and risk to patients or his/her family and receive consent before administration. Read the package insert well before using this drug.
